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Abstract
The aim of this study was to investigate the association between major adverse cardiovascular 
events (MACEs) and inducible ischemia on regadenoson cardiac magnetic resonance (CMR) 
myocardial perfusion imaging (MPI) performed at 3.0 T. Regadenoson stress CMR MPI is 
increasingly used to assess patients with suspected ischemia; however, its value in patient 
prognostication and risk reclassification is only emerging. A total of 346 patients with suspected 
ischemia who were referred for regadenoson CMR were studied. The prognostic association of 
presence of inducible ischemia by CMR with MACEs was determined. In addition, we assessed 
the extent of net reclassification improvement by CMR beyond a clinical risk model. There were 
52 MACEs during a median follow-up period of 1.9 years. Patients with inducible ischemia were 
fourfold more likely to experience MACEs (hazard ratio, 4.14, 95% confidence interval 2.37 to 
7.24, p <0.0001). In the best overall model, presence of inducible ischemia conferred a 2.6-fold 
increased hazard for MACEs adjusted to known clinical risk markers (adjusted hazard ratio 2.59, 
95% confidence interval 1.30 to 5.18, p = 0.0069). Patients with no inducible ischemia 
experienced a low rate of cardiac death and myocardial infarction (0.6% per patient-year), whereas 
those with inducible ischemia had an annual event rate of 3.2%. Net reclassification improvement 
across risk categories (low <5%, intermediate 5% to 10%, and high >10%) by CMR was 0.29 
(95% confidence interval 0.15 to 0.44), and continuous net reclassification improvement was 0.58. 
In conclusion, in patients with clinical suspicion of myocardial ischemia, regadenoson stress CMR 
MPI provides robust risk stratification. CMR MPI negative for ischemia was associated with a 
very low annual rate of hard cardiac events. In addition, CMR MPI provides effective risk 
reclassification in a substantial proportion of patients.
© 2014 Elsevier Inc. All rights reserved.
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Regadenoson, an A2A adenosine receptor agonist, has become one of the most commonly 
used stress agents for myocardial perfusion imaging in the United States1 since its approval 
in 2008. The widespread use of regadenoson relates to its longer half-life, which allows a 
more convenient fixeddose hand injection rather than the continuous infusion required for 
adenosine.2 Pharmacologic vasodilator cardiac magnetic resonance (CMR) myocardial 
perfusion imaging (MPI) has been shown to have excellent diagnostic utility in numerous 
single- and multicenter studies as well as the ability to forecast clinical outcomes.3–5 The 
effectiveness of CMR MPI may be further enhanced by the improved contrast-to-noise ratio 
of 3-T imaging. With recent guidelines from the American Heart Association and American 
College of Cardiology recommending the use of CMR MPI as a reasonable test for the 
evaluation of patients with suspected ischemic heart disease,6 it is expected that the clinical 
use of regadenoson vasodilator CMR MPI will increase. Although there have been 
promising pilot data using regadenoson, these studies have involved a small number of 
patients and have been conducted on 1.5-T systems.7 In the present study, we tested the 
hypothesis that regadenoson vasodilator CMR MPI performed at 3 T provides strong 
prognostic value in patients suspected to have myocardial ischemia.
Methods
We prospectively studied 357 consecutive patients clinically referred for CMR assessment 
of myocardial ischemia. Patients were included if they were >18 years of age and referred 
for assessment of symptoms suspicious of coronary artery disease. Exclusion criteria 
included severe renal dysfunction (glomerular filtration rate <30 ml/min), acute coronary 
syndromes, pregnancy, or absolute contraindication to magnetic resonance imaging. A 
detailed medical history was obtained before each examination.
We performed all regadenoson CMR MPI on a 3.0-T scanner with a 16-element coil (Tim 
Trio/Verio; Siemens Healthcare, Erlangen, Germany) using a protocol consisting of 
vasodilator myocardial perfusion, ventricular function, and late gadolinium enhancement 
(LGE) imaging (Figure 1). All images were acquired with vector electrocardiographic gating 
during breath-hold. Cine steady-state free precession (typical repetition time 3.4 ms, echo 
time 1.2 ms; in-plane spatial resolution 1.6 × 2.0 mm) was used for imaging left ventricular 
(LV) size and function. Myocardial perfusion images were acquired at 3 short-axis segments 
(basal, midventricular, and apical) and 4-chamber long-axis orientation during bolus 
injection of 0.1 mmol/kg intravenous gadolinium diethylenetriamine penta-acetic acid 
(Magnevist; Bayer, Wayne, New Jersey) for stress imaging. A saturation-recovery prepared 
turbo fast low-angle single-shot gradient-echo sequence (typical repetition time 2.4 ms, 
typical echo time 1.0 ms, typical flip angle 18°, 10-ms delay after saturation before readout, 
linear phase-encoding order, acceleration factor 2) with the use of generalized auto-
calibrating partial parallel acquisition (in-plane resolution 2.2 × 2.7 mm, slice thickness 10 
mm, receiver bandwidth 800 to 900 Hz per pixel). Regadenoson (Astellas Pharma US, 
Deerfield, Illinois) was used as the stress agent in all studies. LGE imaging was performed 
at 10 to 15 minutes after contrast.
All images were analyzed with commercial software (QMASS; Medis Medical Imaging, 
Leiden, The Netherlands) at the consensus of 2 independent readers blinded to clinical data. 
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LV volumes (indexed to body surface area) and the LV ejection fraction were obtained by 
manual tracing of end-diastole and end-systole. LGE was semiautomatically quantified 
using full-width half-maximum methods and calculated as total infarct mass and percentage 
of total myocardial mass. A stress perfusion defect was defined as a hypoenhanced region 
>1 pixel in thickness that persisted for ≥3 phases after peak contrast enhancement in a 
coronary distribution. Presence of ischemia was defined as presence of a stress perfusion 
defect in any segment without corresponding LGE. Extent of ischemia was designated on 
the basis of the number of segments out of the American Heart Association and American 
College of Cardiology 17-segment model.
Clinical follow-up after CMR was obtained by mailed questionnaire, review of medical 
records, and contact with patients’ cardiologists. Patients were contacted by telephone if the 
mailed questionnaire was not returned, and a standardized set of questions was used. We 
used a composite end point of major adverse cardiovascular events (MACEs) that included 
cardiac death, new myocardial infarction (MI), late coronary revascularization (>90 days 
after CMR MPI), ventricular arrhythmia (ventricular fibrillation or sustained ventricular 
tachycardia), and hospitalization for unstable angina or heart failure. We also assessed the 
association of CMR MPI findings with a hard composite outcome of cardiac death or acute 
MI. Cardiac death was defined as death preceded by MI, ventricular arrhythmia, 
hospitalization for heart failure, or unstable angina. Ventricular arrhythmias were confirmed 
on telemetry or interrogation of pacemakers or defibrillators, where available. The Social 
Security Death Index was used to confirm all cases of death. Time to event was calculated as 
the period between CMR MPI study and the first occurrence of a MACE. Patients who did 
not experience MACEs were censored at noncardiac death or last follow-up.
Continuous and categorical variables were compared by Student’s t test or Wilcoxon’s rank-
sum test (depending on data normality) and Fisher’s exact test, respectively. Event-free 
survival for those with inducible ischemia was analyzed by Kaplan-Meier estimates (using a 
log-rank test). Univariate associations between clinical and CMR covariates with MACEs 
were assessed by Cox proportional-hazards regression modeling. We built a multivariate 
clinical risk model with a backward elimination Cox regression strategy using p <0.05 as the 
criterion to remain in the model. We also performed logistic regression analyses to 
determine the prognostic association of inducible ischemia presence with MACEs within the 
initial 3 years after CMR study. Finally, we assessed whether inducible ischemia by CMR 
MPI led to net reclassification improvement (NRI) of patient risk, using a validated 
method.8 A 2-sided p-value <0.05 was considered statistically significant. All statistical 
analysis was performed with SAS version 9.3 (SAS Institute Inc., Cary, North Carolina).
Results
We studied 357 consecutive patients referred for CMR MPI. Presenting symptoms included 
chest pain (n = 162 [45%]), new-onset cardiomyopathy (n = 91 [25%]), dyspnea (n = 69 
[19%]), abnormal electrocardiographic findings (n = 24 [7%]), and syncope (n = 11). Eleven 
patients (3%) were excluded for technical reasons. Baseline characteristics stratified by 
inducible ischemia are listed in Table 1. Ninety-three patients (27%) demonstrated inducible 
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ischemia. They were more likely to be older, to be male, to have high prevalence of 
coronary risk factors, and to have lower LV ejection fractions (47% vs 56%, p <0.0001).
The remaining 346 patients were followed for a median of 1.9 years (interquartile range 1.3 
years). There were 52 MACEs (4 cardiac deaths, 4 acute MIs, 6 unstable angina 
hospitalizations, 26 heart failure hospitalizations, 7 arrhythmias, and 5 late coronary 
revascularizations) during the entire follow-up period. In the initial 3 years after CMR MPI 
scanning, 45 of the 52 MACEs occurred. No major complications occurred because of 
regadenoson administration.
In Kaplan-Meier analysis of MACE-free survival, patients with inducible ischemia 
experienced worse MACE-free survival compared with those without inducible ischemia (p 
<0.001; Figure 2). Cumulative MACE rates stratified by the presence of inducible ischemia 
were shown in Figure 3. By univariate Cox regression, patients with inducible ischemia 
were fourfold more likely to experience MACEs (hazard ratio 4.14, p <0.0001; Table 2). For 
every segment of myocardial ischemia, hazards to MACEs on average increased by 12% 
(hazard ratio 1.12, p = 0.0029). Patient age, history of coronary bypass surgery, LV end-
diastolic volume index, and LV end-systolic volume index were selected to form the clinical 
risk model for MACEs. When the presence of inducible ischemia by CMR MPI was added 
to this clinical model, it substantially improved the model (Likelihood ratio chi-square 
increased from 37.25 to 44.41, p <0.01; Table 3). Adjusted for the effects of the clinical risk 
model, patients with inducible ischemia were 2.6-fold more likely to experience MACEs 
(adjusted hazard ratio 2.59, 95% confidence interval 1.30 to 5.18, p = 0.0069). Annualized 
MACE rates were 5.2% (per patient-year) in patients without inducible ischemia and 17.5% 
in patients with ischemia (Figure 4).
When we restricted our analysis to the hard outcomes of cardiac death or acute MI alone, 
inducible ischemia maintained a strong association with these end points (hazard ratio 6.95, 
p = 0.02). Those without inducible ischemia experienced a remarkably low annual rate of 
cardiac death or acute MI (0.6% per patient-year), which compared with a fivefold higher 
average annual rate (3.2%) in patients with inducible ischemia (Figure 4).
Two hundred thirty-three patients (67%) were followed for >3 years. In this subgroup, the 
presence of inducible ischemia portended a 5.2-fold increased risk for MACEs during the 
initial 3 years after CMR MPI. For every segment of inducible ischemia, a 14% increased 
risk for MACEs was observed during the 3 years after CMR MPI. Figure 3 highlights that 
patients without inducible ischemia had a low rate of MACEs in the initial 3 years after 
CMR MPI.
Addition of inducible ischemia to the best clinical multivariate risk model (including patient 
age, history of coronary bypass surgery, LV end-diastolic volume index, and LV end-
systolic volume index) significantly improved risk reclassification for MACEs (continuous 
NRI 0.58, 95% confidence interval 0.22 to 0.95, p = 0.007). Figure 5 depicts the 
reclassification of risk by the addition of inducible ischemia across pretest risk categories of 
low (<5%), moderate (5% to 10%), and high (>10%), where the NRI was 0.29 (95% 
confidence interval 0.15 to 0.44). The NRI for patients who experienced MACEs and those 
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who did not was favorable (0.12 and 0.17, respectively). NRI was most favorable in patients 
initially estimated to be intermediate risk (0.68, 95% confidence interval 0.07 to 1.29).
Discussion
We found that regadenoson CMR MPI performed at 3.0-T provides robust prognostic 
information in patients suspected to have ischemia. Inducible ischemia by regadenoson 
CMR MPI was a strong univariate predictor of MACEs and provided important additive 
information to a baseline clinical risk model. We also demonstrate that normal results on 
regadenoson CMR MPI were associated with favorable outcomes, where the absence of 
inducible ischemia was associated with a low annualized incidence of cardiac death or MI 
(0.6% per patient-year). Abnormal findings on CMR MPI, in contrast, portended 
significantly poorer outcomes, in which inducible ischemia was associated with high rates of 
cardiac events (17% per patient-year). Regadenoson-based CMR MPI performed at 3.0 T in 
patients with suspected ischemia effectively discriminates between patients at high and low 
risk for MACEs and may therefore play an important role in clinical management.
Pharmacologic stress testing represents a sensitive and specific means to identify clinically 
significant ischemic heart disease.9 In an aging population with higher cardiometabolic risk 
patterns,10 pharmacologic stress testing will play an increasingly important role in 
identifying those at highest risk for adverse events, in whom more aggressive medical 
management or revascularization may be warranted. In this context, regadenoson has 
emerged as a commonly used agent in CMRMPI, in which it can measure perfusion 
reserve11 and has been proved effective in patients across body mass index categories.12 
However, recent warnings from the US Food and Drug Administration13 have called into 
question the safety of regadenoson. In addition, there have been limited outcomes data to 
corroborate the prognostic utility of regadenoson CMR MPI in discriminating risk for 
MACEs. The results of our analysis shed light on these issues by demonstrating a robust 
association between inducible ischemia on regadenoson CMR MPI and cardiovascular 
events.
Although adenosine is well established for pharmacologic stress testing,14 regadenoson 
represents an important alternative in light of the infrastructural issues related to magnetic 
resonance scanning. Because of the need for extended tubing and/or magnetic resonance–
compatible infusion pumps to administer adenosine, regadenoson may provide a more 
simplified and cost-effective system. Although adenosine is less expensive per unit dose of 
drug, our institutional observation incorporating the costs of equipment and discarded 
medication has demonstrated a lower cost of using single, fixed-dose regadenoson. The use 
of regadenoson, however, has limitations. Importantly, Bhave et al11 noted that despite 
giving aminophylline 15 minutes after regadenoson, perfusion reserve did not return to 
normal, suggesting that regadenoson may have continued vasodilatory effects even after 
presumed reversibility, limiting the ability to compare “rest” to “stress” images. To avoid 
this limitation, our institution has adopted a protocol that relies solely on the identification of 
stress perfusion defects in areas without LGE.
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The results of our analysis must be viewed in the context of our study design. Although our 
data suggest a strong association between findings on regadenoson CMR MPI and clinical 
outcomes, randomized, multicenter studies with longer follow-up are needed. One potential 
limitation of our analysis is our relatively few “hard end points” and the use of a composite 
clinical end point that included hospitalization for unstable angina or decompensated heart 
failure. Because institutional and individual clinical practices may vary, our results must be 
viewed in this context. A second limitation of our study is that our patients were clinically 
referred and therefore not compared with a control group. Indeed, individuals found to have 
inducible ischemia were older and had higher risk for coronary artery disease. Despite this, 
our multivariate Cox regression, which included age, gender, the ejection fraction, and co-
morbid conditions, found that inducible ischemia was independently associated with adverse 
outcomes. Although prospective, randomized trials are warranted, our data suggest that 
inducible ischemia on regadenoson CMR MPI can add incremental knowledge to clinically 
derived estimates of cardiovascular risk.
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Figure 1. 
CMR MPI protocol totaling approximately 30 minutes in duration.
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Figure 2. 
Kaplan-Meier curve of MACEs stratified by the presence of inducible ischemia.
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Figure 3. 
Cumulative MACE rate observed in the cohort, indicating a relatively low rate of patient 
MACEs within the initial 3 years after CMR MPI.
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Figure 4. 
Annualized event rates of MACEs stratified by the presence of inducible ischemia. (A) 
Cardiac death, MI, late coronary revascularization, ventricular arrhythmia, or hospitalization 
for unstable angina or heart failure. (B) Cardiac death or MI. Comparison p values were 
calculated by chi-square tests.
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Figure 5. 
NRI by CMR presence of inducible ischemia. Pie charts demonstrate proportion of patients 
reclassified by the addition of inducible ischemia across pretest risk categories. Observed 
annualized rates of MACEs for reclassified patients are displayed in bar graphs. Most 
notably in patients with intermediate pretest risk, 18% were reclassified to low risk and 16% 
to high risk, with observed annualized MACE risks of 4.6% and 14.8%, respectively.
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Table 1
Baseline characteristics
Variable All Patients (n = 346) Inducible Ischemia p-Value (Inducible 
Ischemia
vs. No Inducible Ischemia)No (n = 253) Yes (n = 93)
Age (years) 55.1 ± 14.8 52.6 ± 14.3 61.9 ± 13.8 <0.0001
Women 136 (39.3%) 110 (43%) 26 (28%) <0.01
Body mass index (kg/m2) 28.4 ± 6.6 28.1 ± 6.9 29.1 ± 4.8 0.23
Resting Systolic Blood Pressure (mmHg) 127.2 ± 18.6 127.9 ± 18.5 125.3 ± 18.8 0.25
Resting Diastolic Blood Pressure (mmHg) 70.0 ± 12.8 70.1 ± 12.5 69.7 ± 13.6 0.78
Hypertension 173 (51%) 118 (47%) 55 (61%) <0.05
Diabetes 54 (16%) 31 (12%) 23 (25%) <0.01
Smoker 55 (16%) 32 (13%) 23 (26%) <0.01
Hypercholesterolemia 140 (41%) 82 (32%) 58 (65%) <0.0001
Aspirin use 161 (47%) 94 (37%) 67 (74%) <0.0001
Beta-blocker use 173 (50%) 107 (42%) 66 (73%) <0.0001
ACE inhibitor/ARB use 159 (46%) 114 (45%) 45 (49%) 0.54
Statin use 27 (8%) 15 (6%) 12 (13%) <0.05
Nitrate use 39 (11%) 15 (6%) 24 (26%) <0.0001
Calcium Channel Blocker use 42 (12%) 35 (14%) 7 (8%) 0.14
Left ventricular ejection fraction (percent) 53.9 ± 14.8 56.4 ± 15.8 47.4 ± 18.1 <0.0001
Left ventricular end diastolic volume index (mL/m2) 93.4 ± 16.9 88.3 ± 32.8 106.9 ± 44.4 <0.0001
Left ventricular end systolic volume index (mL/m2) 47.4 ± 38 42.0 ± 33.0 61.9 ± 46.1 <0.0001
Left ventricular mass (grams) 118.4 ± 49.7 111.0 ± 47.5 136.7 ± 50.7 <0.0001
Right ventricular ejection fraction (percent) 53.8 ± 9.63 54.4 ± 9.4 52.3 ± 10.0 0.10
Right ventricular end diastolic volume index (mL/m2) 73.1 ± 21.3 72.8 ± 20.4 73.9 ± 23.6 0.69
Right ventricular end systolic volume index (mL/m2) 34.6 ± 15.5 33.9 ± 14.2 36.4 ± 18.6 0.19
Presence of late gadolinium enhancement 145 (42%) 77 (30%) 68 (73%) <0.0001
Late gadolinium enhancement mass (grams) 5.43 ± 12.21 3.7 ± 11.2 10.6 ± 13.7 <0.0001
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Table 2
Univariable associations for major adverse cardiovascular events (cardiovascular death, acute myocardial 
infarction, late revascularization, ventricular arrhythmia, or hospitalization for unstable angina or heart failure)
Univariable Associations
Characteristic Hazard Ratio
(95% CI)
Likelihood
Ratio χ2
p-Value
Demographics
  Age 1.03 (1.02–1.06) 11.1 0.0009
  Women 0.66 (0.36–1.21) 1.81 0.18
  Body Mass Index, per kg/m2 1.00 (0.96–1.04) 0.0002 0.99
  Hypertension 1.78 (0.99–3.22) 3.73 0.05
  Diabetes Mellitus 1.88 (0.99–3.53) 3.80 0.05
  Smoker 1.89 (0.99–3.56) 3.83 0.05
  Dyslipidemia 1.63 (0.92–2.86) 2.85 0.09
  Coronary artery bypass grafting 4.39 (1.97–9.78) 13.0 0.0003
  Myocardial infarction 3.79 (2.06–7.01) 18.2 <0.0001
  Percutaneous coronary intervention 2.69 (1.43–5.08) 9.38 0.002
Medications
  Aspirin use 3.29 (1.77–6.11) 14.1 0.0002
  Beta-blocker use 1.42 (0.80–2.51) 1.45 0.23
  ACE-inhibitor use 1.89 (1.05–3.37) 4.59 0.03
  Statin use 2.10 (1.18–3.75) 6.34 0.01
  Calcium channel blocker use 2.13 (1.06–4.29) 4.50 0.03
Electrocardiographic findings
  Long QT interval (corrected) 4.53 (2.30–8.91) 19.1 <0.0001
  Left bundle branch block 1.28 (0.51–3.23) 0.27 0.60
  Right bundle branch block 2.70 (1.07–6.85) 4.39 0.04
  Left ventricular hypertrophy 1.41 (0.60–3.31) 0.62 0.43
  Q-wave 3.65 (1.99–6.56) 17.9 <0.0001
CMR findings
  Left ventricular ejection fraction 0.95 (0.94–0.97) 34.9 <0.0001
  Left ventricular end diastolic volume index 1.01 (1.00–1.02) 23.3 <0.0001
  Left ventricular end systolic volume index 1.01 (1.01–1.02) 32.1 <0.0001
  Presence of late gadolinium enhancement 4.88 (2.54–9.33) 22.8 <0.0001
  Inducible Ischemia 4.14 (2.37–7.24) 24.7 <0.0001
  Ischemia Severity 1.12 (1.04–1.20) 8.89 0.0029
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Table 3
Incremental prognostic value of perfusion defect by CMRMPI beyond known risk markers of major adverse 
cardiovascular events. Model 1 represents the base (referent) clinical model to which inducible ischemia 
(Model 2) is added to assess incremental prognostic association with major adverse cardiovascular events
Model 1 Model 2
Statistic p-Value Statistic p-Value
Model Global χ2 37.25 Referent 44.41 <0.01
Hazard
Ratio
p-Value Hazard
Ratio
p-Value
Age (per year) 1.02 0.16 1.01 0.48
Coronary artery bypass grafting 2.74 0.039 1.83 0.22
Left ventricular end diastolic volume index 0.97 0.036 0.97 0.03
Left ventricular end systolic volume index 1.05 0.0028 1.05 0.003
Inducible ischemia — — 2.59 0.0069
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